1.
World Health Organisation. Prevention and control ofherpesvirus diseases. Part 1. Clinical and laboratory diag-nosis and chemotherapy. A WHO meeting. Bull WHO1985; 63(2):185-201.
2.
Leone P.A., Trottier S., Miller M. Valacyclovir for episod-ic treatment of genital herpes: a shorter 3-day treatmentcourse compared with 5-day treatment. Clin Infect Dis2002; 34:958-62.
3.
Patel R., Bodsworth N., Woolley P., et al. Valaciclovir forthe suppression of recurrent genital HSV infection: aplacebo controlled study of once-daily therapy.Genitourin Med 1997; 73:105-9.
4.
Corey L., Wald A., Patel R., et al. Once daily valacyclovirto reduce the risk of transmission of genital herpes. NEngl J Med 2004; 1:11-20.
5.
Spruance S.L, Jones T.M., Blatter M.M., et al. High-Dose,short-duration, early valacyclovir therapy for episodictreatment of cold sores: results of two randomized, place-bo-controlled, multicenter studies. Antimicrob AgentsChemother 2003; 47:1072-80.
6.
Beutner K.R., Friedman D.J., Forszpaniak C., et al.Valaciclovir compared with acyclovir for improved ther-apy for herpes zoster in immunocompetent adults.Atimicrobial Agents Chemother 1995; 39:1546-53.
7.
Feinberg J.E., Hurwitz S., Cooper D., et al. A randomized,double-blind trial of valaciclovir prophylaxis forcytomegalovirus disease in patients with advancedhuman immunodeficiency virus infection. J Infect Dis1998; 177:48-56.
8.
Lowance D., Neumayer H.H., Legendre C.M., et al.Valacyclovir for the prevention of cytomegalovirus dis-ease after renal transplantation. N Engl J Med 1999;340:1462-70.
9.
Ljungman P., de la Camara R., Milpied N., et al.Randomized study of valacyclovir as prophylaxis againstcytomegalovirus reactivation in recipients of allogenicbone marrow transplants. Blood 2002; 99:3050-6.
10.
Egan J.J., Carroll K.B., Yonan N., et al. Valacyclovir pre-vention of cytomegalovirus reactivation after hearttransplantation: a randomized trial. J Heart LungTransplant 2002; 21(4):460-6.